LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

JNJ

163.28

-0.06%↓

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

JNJ

163.28

-0.06%↓

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

JNJ

163.28

-0.06%↓

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

JNJ

163.28

-0.06%↓

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

JNJ

163.28

-0.06%↓

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

Search

Adaptive Biotechnologies Corp

Cerrado

8.69 3.45

Resumen

Variación precio

24h

Actual

Mínimo

8.4

Máximo

9

Métricas clave

By Trading Economics

Ingresos

-1.6M

-34M

Ventas

1M

47M

BPA

-0.228

Margen de beneficio

-71.044

Empleados

619

EBITDA

-1.8M

-26M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+13.93% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-77M

1.1B

Apertura anterior

5.24

Cierre anterior

8.69

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 mar 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise as Concerns About U.S. Tariffs Ease -- Market Talk

24 mar 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; May Be Weighed by Easing Worries Over U.S. Tariffs -- Market Talk

24 mar 2025, 23:27 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology: Accelerating Development of New Quality Productive Forces >1157.HK

24 mar 2025, 23:27 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology: Continuously Improving Scientific Research and Innovation >1157.HK

24 mar 2025, 23:25 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology: To Fully Establish Overseas Business System >1157.HK

24 mar 2025, 23:24 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology: Accelerating Development of Industrial Echelons >1157.HK

24 mar 2025, 23:21 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology 2024 Net CNY3.52B Vs. Net CNY3.55B >1157.HK

24 mar 2025, 23:20 UTC

Ganancias

Zoomlion Heavy Industry Science and Technology 2024 Rev CNY45.48B Vs. CNY47.08B >1157.HK

24 mar 2025, 22:08 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

James Hardie's Azek Buy Will Take Some Time to Digest -- Market Talk

24 mar 2025, 22:06 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Gold Fields, Gold Road Relationship Turning Frosty -- Market Talk

24 mar 2025, 21:18 UTC

Principales Noticias

FBI Launches Task Force to Investigate Threats Against Tesla -- Barrons.com

24 mar 2025, 21:03 UTC

Principales Noticias

FBI Launches Task Force to Investigate Threats Against Tesla -- Barrons.com

24 mar 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

24 mar 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

24 mar 2025, 20:42 UTC

Principales Noticias

Boeing Is Pushing to Withdraw Guilty Plea Agreement -- WSJ

24 mar 2025, 20:32 UTC

Ganancias

Boeing Gains and Lockheed Stock Falls Further After Fighter Jet Upset -- Barrons.com

24 mar 2025, 20:32 UTC

Principales Noticias

U.S. Stocks Rally After Latest Twist in Tariff Saga Eases Investors' Worries -- WSJ

24 mar 2025, 20:17 UTC

Principales Noticias

Dow Gains About 600 Points on Tariff Optimism -- WSJ

24 mar 2025, 20:16 UTC

Principales Noticias

FBI Launches Task Force to Investigate Threats Against Tesla -- Barrons.com

24 mar 2025, 20:09 UTC

Charlas de Mercado

Canada Consumer Confidence Hits New Low, Labor Expectations Sour -- Market Talk

24 mar 2025, 19:25 UTC

Charlas de Mercado

U.S. Natural Gas Loses Ground on Mild Weather Outlook -- Market Talk

24 mar 2025, 19:10 UTC

Charlas de Mercado

Oil Gains As Trump Aims at Buyers of Venezuelan Crude -- Market Talk

24 mar 2025, 18:59 UTC

Charlas de Mercado

Gold Backtracks As Investors Stay Cautious -- Market Talk

24 mar 2025, 18:46 UTC

Charlas de Mercado

Telus' Cash Flow From Digital Business Isn't Seen as Impairment -- Market Talk

24 mar 2025, 18:03 UTC

Principales Noticias

Dow Gains About 500 Points on Tariff Optimism -- WSJ

24 mar 2025, 17:57 UTC

Principales Noticias

Fed's Bostic Sees Only One Rate Cut This Year, Down From Prior Forecast Of Two Moves -- MarketWatch

24 mar 2025, 17:50 UTC

Principales Noticias

Trump Says Auto, Pharma Tariffs Coming Soon, but Doesn't Mention April 2 -- WSJ

24 mar 2025, 17:46 UTC

Principales Noticias

BYD Stock Jumps. Car Sales Topped Tesla's for First Time. -- Barrons.com

24 mar 2025, 17:38 UTC

Charlas de Mercado

Small Impact Seen From Venezuelan Crude-Related Tariffs -- Market Talk

24 mar 2025, 17:02 UTC

Ganancias

Affirm Stock Has 'Plenty of Greenfield' Ahead. These Are the Challenges. -- Barrons.com

Comparación entre iguales

Cambio de precio

Adaptive Biotechnologies Corp Esperado

Precio Objetivo

By TipRanks

13.93% repunte

Estimación a 12 meses

Media 9.57 USD  13.93%

Máximo 12 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

7.58 / 8.66Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.